Dagmar Rosa-Bjorkeson, Novartis
S
Dagmar Rosa-Bjorkeson
VP, Respiratory Franchise, Novartis
SECRET TO SUCCESS: "It's the vision that I provide. I am strategic. I have passion and I care, so people will follow."
ROLE MODEL: Deborah Dunsire, who led Novartis' oncology business unit
Dagmar Rosa-Bjorkeson came by her global vision for pharma honestly: She grew up in Puerto Rico, studied chemistry and business in the States, joined Swiss-based Novartis, and later became general manager for Sweden.
Dagmar Rosa-Bjorkeson
Along the way, in 2001, she was tapped to head the launch of eczema drug Elidel—and like any self-respecting emerging leader, she ran with the challenge. "I aligned a whole launch team to deliver more than anybody thought the drug could do," she recalls. "That was a turning point in my career, because I had visibility at the global level."
A few promotions later, the new VP of Novartis' respiratory franchise is charged with growing the $700 million domestic market into a multi-billion dollar cash cow. But as a leader, Rosa-Bjorkeson (44) isn't only about results. "I want to create the best culture that supports a patient-centered focus with talented people who want to come to work every day—and I can pretty much guarantee the best results possible." It should come as no surprise that this mother of three describes herself as "big on quality of life." That's the kind of value one hopes will influence the next generation of leaders.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
